PICATO

This brand name is authorized in Brazil, Estonia, Lithuania, Poland, Romania, United States

Active ingredients

The drug PICATO contains one active pharmaceutical ingredient (API):

1 Ingenol mebutate UNII 7686S50JAH - INGENOL MEBUTATE

Picato is indicated for the cutaneous treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis in adults. The mechanism of action of ingenol mebutate for use in actinic keratosis remains to be fully characterised. Results from two clinical studies on biological effects of ingenol mebutate have shown that topical administration induced epidermal necrosis and a profound inflammatory response in both epidermis and the upper dermis of the treated skin, dominated by infiltrating T cells, neutrophils and macrophages. Read about Ingenol mebutate

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
PICATO Gel	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
D06BX02		D Dermatologicals → D06 Antibiotics and chemotherapeutics for dermatological use → D06B Chemotherapeutics for topical use → D06BX Other chemotherapeutics
Discover more medicines within D06BX02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 541112120001102
Country: EE	Ravimiamet	Identifier(s): 1598698, 1598700
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1068377, 1068378
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100295535, 100295630
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W59715001, W59716001
Country: US	FDA, National Drug Code	Identifier(s): 50222-502, 50222-503